Cenix BioScience and Schering AG Sign Research Agreements to Advance Several Disease Programs
Both projects, which started in the last quarter of 2004, focus on the cell-based validation by Cenix of collections of candidate genes previously identified by Schering AG as possible therapeutic drug targets. Cenix is applying its industry-leading expertise in combining high throughput (HT) RNAi with high content (HC) phenotype analyses in mammalian cells to deliver an efficient, detailed characterization of target-specific loss-of-function phenotypes. These data, along with associated insights into the functions of these targets, will provide Schering AG with the solid, patho-physiologically relevant criteria needed to prioritize targets for advancement in their drug development programs.
Cenix will apply streamlined HT validation of RNAi reagents and proprietary HT-RNAi assays including functional readouts based on rich, multi-parameter analyses. The project, which will make use of several human and mouse cell lines, will advance research programs at Schering AG. No financial terms were disclosed.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.